SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Kosan BioSciences -- KOSN
An SI Board Since May 2001
Posts SubjectMarks Bans Symbol
933 40 0 KOSN
Emcee:  tuck Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
583[17-AAG beats several receptor tyrosine kinase inhibitors against synovial sarcotuck-8/3/2005
582Kosan Biosciences 2Q Losses 25c/Shr Vs 18c DOW JONES NEWSWIRES July 28, 2005 7:3Jim Oravetz-7/28/2005
581News release out this AM, NO BIG DEAL, 35 MM line of credit. But for the vol. Bill Tomko-7/18/2005
580My fault, Erik. I wasn't referring to KOSN but to the overall strength in bitom pope-7/16/2005
579>>my guess is short covering>> The short position is very small. OnIcebrg-7/16/2005
578I certainly know nothing, but my guess is short covering because the seasonal wetom pope-7/15/2005
577And what was that today? Strong biotech market, granted, but that was exceptionaBiomaven-7/15/2005
576Infinity Initiates Phase I Clinical Trial of IPI-504 for Multiple Myeloma Mondayscaram(o)uche-7/11/2005
575boston.com Infinity adds improvisation to drug quest By Scott Kirsner | July scaram(o)uche-7/11/2005
574Early in-vito , and not in humans but this strikes me as a very encouraging dataBill Tomko-7/8/2005
573[17-AAG overcomes TRAIL resistance in colon cancer cell lines] >>Biochem tuck-7/7/2005
572Always some concern if the General counsel or CFO are being forced out, why, whaBill Tomko-7/2/2005
571Certainly looked that way to me.... resigned, but after having been asked to dscaram(o)uche-7/2/2005
570Thanks. It was helpful. The employment post raised some questions in my mind, seBill Tomko-7/1/2005
569couldn't find it either. they used to be published in <i>Cancer Reseascaram(o)uche-7/1/2005
568>>Cancer Chemother Pharmacol. 2002 Jan;49(1):7-19. Pharmacokinetics, tistuck-6/30/2005
567Item 1.01. Entry into a Material Definitive Agreement. On June 24, 2005, thescaram(o)uche-6/30/2005
566can you also provide translations--(;->)Bill Tomko-6/30/2005
565[17-DMAG preclinical data] >>Cancer Chemother Pharmacol. 2005 Jun 29; [Eptuck-6/30/2005
564Again thanks, Not sure I understand either B-U-T--> I am confused now on a muBill Tomko-6/29/2005
563[Geldanamycin derivative inhibition of HGF/SF-mediated Met tyrosine kinase receptuck-6/29/2005
562Once again a Million thanks guys. One more very encouraging data point.Bill Tomko-6/26/2005
561Blood. 2005 Jun 21; [Epub ahead of print] ZAP-70 is a novel conditional heat sscaram(o)uche-6/25/2005
560[Hsp90 inhibitors versus CLL via degradation of ZAP-70] >>Blood. 2005 Juntuck-6/24/2005
559We're certainly ahead of them on the PI 17AAG results. Not really expectingtuck-6/17/2005
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News